Economic evaluation of interventions for the treatment of asthma in children:a systematic review by Adél Halmai, Luca et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Economic evaluation of interventions for the treatment of asthma
in children
Citation for published version:
Adél Halmai, L, Neilson, AR & Kilonzo, M 2019, 'Economic evaluation of interventions for the treatment of
asthma in children: a systematic review', Pediatric Allergy and Immunology.
https://doi.org/10.1111/pai.13129
Digital Object Identifier (DOI):
10.1111/pai.13129
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
Pediatric Allergy and Immunology
Publisher Rights Statement:
This is the author’s peer-reviewed manuscript as accepted for publication.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Oct. 2020
This article has been accepted for publication and undergone full peer review but has not been through the 
copyediting, typesetting, pagination and proofreading process, which may lead to differences between this 
version and the Version of Record. Please cite this article as doi: 10.1111/pai.13129
This article is protected by copyright. All rights reserved
Economic evaluation of interventions for 
the treatment of asthma in children:
a systematic review
Luca Adél Halmai1, 
Aileen Rae Neilson 2, 
Mary Kilonzo3
1 The review was undertaken as part of an academic MSc dissertation research project at the 
University of Aberdeen, Present institutional affiliation: MediConcept Ltd., Health Economics 
Department (Budapest, Hungary)
2 Edinburgh University, Usher Institute of Population Health Sciences and Informatics (School of 
Molecular Genetic and Population Health Sciences) (Edinburgh, United Kingdom)
3 University of Aberdeen, Health Economics Research Unit (Aberdeen, United Kingdom)
Running title: Economic evaluation of paediatric asthma 
Correspondence: Luca Adél Halmai, MediConcept Ltd., Health Economics Department 
(Budapest, Hungary), Email: l.a.halmai.16@aberdeen.ac.uk
Word count: 3,500 words
Number of tables and figures: 2
Number of supplementary appendix: 3
A
cc
ep
te
d 
A
rt
ic
le
i Conflict of interests 
There are no competing interests. 
ii Funding information 
This research did not receive any specific grant from funding agencies in the public, 
commercial or not-for-profit sector. 
 
 This article is protected by copyright. All rights reserved 
iii Abstract 
 
Objectives: This systematic review aims to identify and critique full economic evaluations 
(EEs) of childhood asthma treatments with the intention to guide researchers and 
commissioners of paediatric asthma services towards potentially cost-effective strategies. 
 
Methods: ‘MEDLINE’, ‘Embase’, ‘Econlit’, ‘NHS EED’, and ‘CEA’ databases were searched 
to identify relevant EEs published between 2005 and May 2017. Quality of included studies 
was assessed with a published checklist. 
 
Results: Eighteen studies were identified and comprised one cost-benefit analysis, 11 cost-
effectiveness analyses, one cost-minimisation analysis, and six cost-utility analyses. 
Treatments included pharmaceutical (n=11) and non-pharmaceutical (n=7) interventions. 
Fourteen studies identified cost-effective strategies. The quality of the studies varied and 
there were uncertainties due to the methods and relevance of data used.  
 
Conclusion: Good quality economic evaluation studies of paediatric asthma treatments are 
lacking. EE of new technologies adapted to local settings is recommended and can result in 
cost-savings. 
 
Key words: adverse childhood experience, asthma, child, cost-effectiveness, costs 
and cost analysis, economic evaluation, respiratory tract diseases, systematic review 
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iv Main text 
Introduction 
 
Asthma is a chronic inflammatory disease which narrows the airways1 and leads to reduced 
airflow during inhalation and exhalation2. Asthma often manifests in childhood3 and can lead 
to severe or life-threatening consequences. The disease cannot be cured1; however, it can 
be effectively treated by symptoms control and risk reduction against future adverse 
outcomes3-6. Treatment is substantial for all ages while the burden of symptoms impairs the 
patients’ everyday life and has a considerable negative impact on its quality7,8. 
The management of asthma encompasses pharmaceutical9,10 and non-pharmaceutical 
strategies (e.g. education techniques, self-management, and environmental controls9). In 
children, the disease control and management differ from those of the adult population. Until 
children fully possess emotional, cognitive and physical development to understand and 
manage the disease entirely on their own, their parents and caregivers have a considerable 
influence on their medical decisions11.  
Worldwide, the prevalence of asthma is roughly around 235 million as reported by the World 
Health Organisation (WHO). In the United Kingdom (UK) asthma affects approximately 5.4 
million people (including about 1.1 million children), and the estimated cost of illness is 
around £1.1 billion, and it is likely to increase9,12-14. 
Systematic reviews (SRs) assessing the cost-effectiveness of treatments are essential to 
guide policy decisions about those interventions which offer ‘good value for money’ versus 
those which are of ‘poor’ value. Economic evaluations (EEs) are used to provide a rational 
and transparent decision-making framework to make well-informed decisions. In health care, 
EEs help to identify new alternatives and evaluate the evidence on the cost-effectiveness of 
different programs, by comparing the alternatives regarding both their costs and 
consequences/benefits15.  
 
Full EEs address both the costs and consequences. They have a similar method of 
assessing the costs. However, the method used to measure the benefits of the interventions 
is different15.  
 Cost-benefit analysis (CBA) - measures both the outcomes and costs in monetary 
units, e.g. willingness to pay (WTP); A
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 Cost-consequences analysis (CCA) - considers all the costs and benefits of the 
interventions and reports them without aggregation; 
 Cost-effectiveness analysis (CEA) – uses natural units (e.g. life years gained, asthma 
attacks prevented) to assess the benefits. It involves the calculation of the 
incremental cost-effectiveness ratio (ICER), which shows the additional cost per unit 
of achieving an outcome while comparing it to an alternative treatment16. To measure 
the value for money, the ICER needs to be compared with a predefined cost-
effectiveness threshold15 that is applied to distinguish interventions which are cost-
effective with ones which are not cost-effective;  
 Cost-minimisation analysis (CMA) - focuses just on costs and assumes equal 
benefits; 
 Cost-utility analysis (CUA) - expresses the outcome as a utility which incorporates 
the consumers’ preferences into the valuation, typically measured as quality-adjusted 
life years (QALYs)15. 
A few SRs conducted of EE studies for the treatment of childhood asthma were identified. 
Ungar 200917 only assess paediatric population, while further reviews assessed both adult 
and paediatric population EEs18-22. This current review aimed to systematically review and 
critically appraise the literature of EEs that focusses specifically on paediatric asthma and 
takes a broader view of eligible treatments (both pharmaceutical and non-pharmaceutical 
interventions).  
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Methods 
The search process, screening, data extraction and quality assessment was done by one 
reviewer (LH) based on pre-defined criteria.  A second reviewer (AN) was involved when 
there was uncertainty. 
Search strategy 
A systematic search was performed to identify full EEs of paediatric asthma interventions 
published between 2005 and May 2017. English language articles were searched in multiple 
databases: 
 ‘CEA Registry’, 
 ‘ECONLIT’ 
 ‘EMBASE’ 
 ‘National Health Service (NHS) Economic Evaluation Database (EED)’,  
 ‘Ovid MEDLINE’. 
An additional hand search was carried out for conference abstracts and study protocols 
identified in the online databases. The search strategy drew from recommended filters such 
as Kua et al.23, NHS EED24 and Cochrane Library25.  The mixture of the following terms was 
employed to identify the study population: ‘Adolescent’, ‘Teenager’, ‘Teen’, ‘Preteen’, ‘Pre-
teen’, ‘Young’, ‘Youth’, ‘Young one’, ‘Paediatric’, ‘Children’, ’Child’ and ‘Young people’ and 
‘Child’ and ‘Adolescent’ (MeSH). To identify the condition, ‘Asthma’ (MeSH) and ‘Asthma,’ 
‘Asthma exacerbation’. To recognise Randomized Control Trials (RCTs) and economic 
evaluations, terms from the research filters were used24,25. The search began in 2005 and 
included a two-year overlap with the formerly conducted SR17. This overlap reduces the 
possibility of missing relevant studies due to the methodological differences of the reviews 
(e.g. Ungar 200917 searched only two databases). Studies conducted in the joint period and 
covered in Ungar 200917 were excluded from the current review. 
 
Study selection and Data extraction 
Inclusion criteria: 
 paediatric populations (<18 years) 
 mixed-population (both adults and children) studies if separate analysis for children 
available 
 no restriction on the interventions or comparators 
 full EEs conducted alongside RCTs together with model-based EEs  A
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Exclusion criteria: 
 no population age reported 
 no separate analysis for children in mixed-population studies 
 RCTs with a small sample size (<20 children in each group)  
 illnesses, diagnostic tests or those not directly assessing asthma treatment  
 costing studies only 
 qualitative studies, letters, editorials, case reports, SRs and reviews 
 
Search results were summarised, and duplicates were filtered out both by hand and using 
RefWorks software. Initial screening was carried out at the title-abstract level, then the full-
text article was assessed for the selected, potentially relevant or ambiguous studies.   
Data extraction was based on Kua et al.23 and Campbell et al.18. Information on the 
characteristics of the included studies (author, year, country, study design, setting, type of 
EE, population studied, comparators), details on their methods (perspective, time horizon, 
discount rate, costs, outcomes), results and conclusion were extracted.  
The SR aimed to conduct a qualitative data synthesis and a narrative summary of the review 
findings. 
Quality assessment of EEs 
For appraising the quality of the selected studies, the ISPOR Consolidated Economic 
Evaluation Reporting Standards (CHEERS) statement26 was used. CHEERS is a validated, 
24-item checklist for judging the reporting quality of studies. Answers to the checklist include 
‘yes’, ‘no’, ‘unclear’ or ‘not applicable’. When conducting the quality assessment of studies, 
the percentage of ‘yes’ answers given to the questions in the checklist were considered. 
A narrative summary of the characteristics of the included studies, sources of unit costs and 
measures of benefits/outcomes was conducted to gain further potential information on their 
methodological quality. 
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Results 
Following the removal of study duplicates, 200 titles and abstracts were screened from 
which 165 studies were excluded. Eighteen of the 35 studies selected to assess the full text 
met the inclusion criteria and were included in this review. Figure 1 contains details of the 
literature search process. 
Main study characteristics 
Most of the 18 studies27-44 included originated from the United States of America (USA) 
27,28,32,34,35,38,43, followed by the UK29,31,36, Colombia40,41, the Netherlands42,44, Canada30, 
Germany37, Hong Kong33 and Venezuela39 (see Appendices). 
The population in the studies represented a broad age range (0-18 years). Two studies31,44 
assessed a mixed-population, although only the results restricted to paediatric patients were 
considered. The asthma type and severity of the included studies differed, including 
allergic37, persistent35,40,41, acute36,39 and chronic31 asthma. 
The settings of the studies varied: nine hospital-based27,30,32,33,35,36,39,42,44 , three school-
based28,34,40, a hospital- and school-based38, a study centre-based43 intervention and four 
studies29, 31, 37, 41  did not report the study setting.  
The type of EEs included, ten CEAs27,28,30,32-35,37,42,43, five CUAs29,31,40,41,44, a CMA39, a 
CBA38, and one study36 included both a CEA and CUA. According to study design, twelve 
studies were trials28,32-39,42-44, and six were models27,29-31,40,41. 
To inform the estimates of treatment effectiveness, three models reported synthesising data 
from RCTs29,40,41, one from an SR30, one31 from a meta-analysis and one model27 did not 
state the source of data. 
Eight studies29,31-33,35,37-39 did not explicitly report the perspective of the study. Other studies 
used: societal28, hospitals’ 30, health care system40,41 and both societal and health care 
system27,42-44 perspectives. 
The time horizon in modelling studies ranged from approx. four days30 to ten years29, while 
in trial based EEs was between a month36 and three years37. 
Eleven studies27,28,32-35,38,39,42-44 did not report whether they used discounting – which is a 
method for adjusting all future costs and benefits to their present day values15, although  
discounting would not be appropriate in ten of these studies27,28,32-35,38,42-44 as they used time 
horizons of less than one year. Five studies30,31,36,40,41 reported that discounting was not 
required and two further studies used a discount rate of 3%37, 3.5%29. A
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Comparators/interventions 
Eleven pharmaceutical27,29-31,35-37,39-41,43 and seven non-pharmaceutical interventions28,32-
34,38,42,44 were identified. Two28,33 of the non-pharmaceutical interventions included 
educational interventions:  
 intensive asthma education program vs. standard program33 
  “Power Breathing” program, which focuses on asthma education, control strategies, 
and their psychosocial effects vs. no intervention28.  
 
The further five studies32,34,38,42,44 were management programs: 
 Peer-led asthma self-management program vs. an adult-led one38  
 School-Based Asthma Therapy (SBAT) program vs. no treatment34 
 nurse-led tele-monitoring program vs. usual care (UC)44 
 Real-Time Medication Monitoring (RTMM) with Tailored short message service 
(SMS) reminders vs. a control group without SMS reminders42  
 parent mentor (PM) program which provided help and advice to families to enhance 
the children’s asthma management vs. UC32.   
 
The eleven studies that included pharmaceutical interventions27,29-31,35-37,39-41,43 examined 
the following treatments and comparators:  
 prescribed and dispensed inhaled corticosteroids vs. UC27 
 daily inhaled corticosteroids vs. Intermittent inhaled corticosteroids40 
 omalizumab+ standard therapy vs. standard therapy29 
 fluticasone propionate (FP) vs. montelukast (MON)35,43  
 salmeterol/fluticasone propionate combination (SFC) corticosteroid vs. FP versus 
beclomethasone dipropriate (BDP)31 
 budesonide (BUD) vs. FP vs. BDP41 
 nebulised magnesium sulphate (MgSO4) vs. placebo36 
 one dose of nebulised formoterol fumarate (FF) vs. three doses of nebulised 
Albuterol ampoules39 
 Subcutaneous Specific Immunotherapy (SCIT) plus asthma medication vs. 
medication only37 
 metered-dose inhaler (MDI) vs. wet nebulizer30 
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Outcomes   
All CEAs assessed asthma-related outcomes such as: symptom-free days (SFD)28,34, 
asthma control days42,43. The CBA study38 calculated net cost savings and the CMA39 
contrasted the cost of two treatments after comparing the patient’s vital parameters to 
confirm the two treatments were equal in terms of their effectiveness presumably. The 
primary outcome of CUAs29,31,36,40,41,44 was QALYs. 
 
Findings of the studies 
The findings of the included studies are reported narratively because of the heterogenous 
nature of the data and the use of a meta-analysis was inappropriate. The use of a network 
meta-analysis was outside of the scope of this present study. 
From the eleven CEAs (including Petrou et al.36, which incorporated both a CEA and CUA), 
eight27,28,32-34,36,37,42 compared the intervention to placebo, UC, control group or standard 
therapy and three30,35,43  involved different active treatments. Within the group that compared 
the intervention to placebo, seven articles27,28,32-34,36,37   stated that the new intervention was 
more cost-effective than the comparator. From the seven studies, only three32,34,36 reported 
the ICER, which found that the cost-effectiveness of the SBAT program cost on average 
$10/an additional SFD gained. Petrou et al.36 demonstrated that the MgSO4 along with the 
standard therapy could show 75.1% cost-effectiveness at the £1,000/unit decrement in 
Asthma Severity Score (ASS) (ICER=£189). The PM program32 was associated with cost 
savings, attaining an ICER of -$597.10/asthma exacerbation-free day gained. Vasbinder et 
al.42 concluded that there was no evidence on better asthma control in the intervention group 
except adherence and no difference in costs were identified, apart from the price of the SMS 
intervention. 
 
Studies not reporting ICER showed positive results, for example, toward the “Power 
Breathing” program. This program was more cost-effective than the control group with the 
cost of $3.90/participant/SFD gained28.. Reinhold et al.37 estimated the probability of SCIT 
being cost-effective at around 90%. Ng et al.33 reported that the intensive asthma programs 
could be less costly, as it was associated with HK$969 net saving per patient. Andrews et 
al.27 found that switching to an alternative delivery method could be beneficial both clinically 
and financially. The medication “dispensing” arm was linked with $7,000 total cost savings 
compared to UC.  
 A
cc
ep
te
d 
A
rt
ic
le
 This article is protected by copyright. All rights reserved 
The three trial-based CEAs30,35,43 that compared active treatments revealed cost-effective 
therapies. The MDI was associated with an ICER of CA$2,499/admission averted compared 
to the wet nebulization technique30. The treatment with FP was cost saving43. Ostrom et al.35 
found that asthma-related costs were not only lower for FP, but it was also more effective 
than MON (no ICER reported). 
  
Three CUAs29,36,44 included the use of UC as the comparator but none of the studies showed 
positive results in favour of the new intervention. Willems et al.44 found that the nurse-led 
tele-monitoring program had only 22% probability of being cost-effective at the 
€40,000/QALY threshold. Petrou et al.36 found that the probability of the nebulized MgSO4 
being cost-effective at the accepted threshold level was only 68.6%. Burch et at29 revealed 
that the use of omalizumab for children age six-eleven is not cost-effective at the £20,000-
30,000/QALY threshold (ICER=£91,169).  
  
Three further CUAs31,40,41 that compared active treatments found that as stated in 
Rodriguez-Martinez et al. 201341 BDP was the most cost-effective method when the WTP 
was below £21,129.22/QALY. Doull et al.31 found a particular type of SFC (Evohaler) to be 
the most cost-effective with the ICER £15,739/QALY gained. In Rodriguez-Martinez et al. 
201540 daily therapy with ICS was considered dominant. 
 
Rhee et al.38, (CBA), found that the peer-led program yields more healthcare cost savings 
than the adult-led one. Rodriguez et al.39, (CMA), revealed that using a single dose of 
nebulised FF powder could not only be simpler but also cheaper than three doses of 
nebulised Albuterol ampoules. 
 
Quality assessment of the included EEs and evidence 
The average reporting quality score of the studies based on the CHEERS checklist was 
70.61%, standard deviation: 13.88% (see Table 1). Summarising the results of the checklist 
shortcomings in describing uncertainty, price date and conversion details, discounting were 
identified. However, the included studies seem to be strong in reporting general information 
when conducting an EE (e.g. time horizon, health outcomes, model assumptions for models, 
settings or location), and at describing limitations and study findings (see Appendices). 
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Discussion 
Main findings 
This SR provides a summary of recent treatments available to treat childhood asthma. The 
SR focussed specifically on the paediatric population which allowed us to include a broad 
scope of asthma treatments that is slightly different than in other recent reviews. 
A total of the 18 studies27-44 were included in this review which incorporated various asthma 
therapies with differing degree of cost-effectiveness. The studies were heterogeneous as 
they originated from different countries, the year of publication varied, and they included 
different types of EEs and various outcomes. The reporting quality of the studies varied 
greatly. Key aspects of the methodology of the included studies were further examined, and 
the investigation suggests uncertainties around the results due to the methods and the 
relevance of the data used. The age range of the study population differed in the studies, 
and some of them accepted 17-18 years old patients30,38,39,41, who might not appropriately 
represent children; moreover, the detailed information on the distribution of age and gender 
in the groups were incomplete. Information on allocation concealment, blinding, and loss to 
follow-up were not available in each trial.  
The time horizon of the studies was relatively short even in the models. The lack of 
examination of long-term consequences begs the question of whether the results of the 
studies would still be robust when extrapolated to a longer period or a lifetime. Also, 
sensitivity analyses were not contained in all studies to explore any uncertainty (surrounding 
model assumptions, data sources etc.) and their potential impact on the study results.  
The interpretation and comparability of results were restricted since the asthma treatment 
protocol, and clinical guidelines differed in the countries, meaning that some essential 
asthma medications were not available in low and middle-income countries40, or the dose of 
medicines was not licensed for specific age groups31. 
Some studies remarked at the lack of research available on their topic. Studies31,37 
experienced restrictions in comparing their results with the findings of previous research 
because those were not available or they32,36,39,43 outlined that their research was the first in 
examining the cost-effectiveness of the particular treatment. The generalisability of the 
results to other similar settings and populations with the same characteristics should be 
confirmed by future research28,32,36 with, for example, a larger sample size for trial-based 
EEs.  A
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Two studies27,41 hinted that the unit costs they used, might not be representative of the whole 
asthma paediatric population of the country. Furthermore, studies30,31,38 acknowledged that 
the preferences they used might be misleading. Preferences are patient-reported values that 
are converted to an index score to measure the health-related quality of life45. Four 
studies29,31,36,44 reported the use of EuroQol five-dimensions questionnaire (EQ-5D) or Short-
Form Six-Dimension questionnaire (SF-6D) to obtain the preferences.  Rodriguez-Martinez 
et al. 201341 and 201540 reported the use of a health state utility valuation survey. However, 
the National Institute for Health and Care Excellence (NICE) recommends the use of the EQ-
5D to obtain utility scores, it is not validated in children46. That is, a value set for children 
does not yet exist and so most EE studies apply the adult value set instead to obtain health 
state utility values for children. Both Noyes et al.47 and Willems et al.48 used EQ-5D in their 
research and they recommend its use.  
Generalisability was limited due to the diverse cost sources, differing perspectives which 
means that different types of costs were considered in each perspective.  
The current review faces similar difficulties in cross-study comparison as Kim et al.20 does 
and it supports the need for standardised data sources and methods. Similar to the general 
findings of Rodriguez-Martinez at al. 201822 the results of our review also found the quality of 
the reporting of the study methods to be variable, so introducing the potential for some 
uncertainties in several important aspects relating to the methods and relevance of data 
used. 
 
The strengths and limitations reported by the study authors’ themselves suggest that the 
current quality of the economic evidence base appears to be moderate and there is some 
uncertainty around the long-term cost-effectiveness and generalisability of the study's 
findings. 
 
 However, the review can further guide the design of future EEs by highlighting key parts that 
should be considered when conducting a study or publishing it. To improve the current 
landscape of EEs of paediatric asthma interventions research with high quality of evidence, 
relevant and robust methods is needed.  
Context with other reviews 
SRs have been identified that contain EE studies concerning the treatment of childhood 
asthma. While Ungar17 is limited to paediatric population, the others assess both adult and A
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paediatric population. Though the full search strategy of the study17 was not available to the 
researcher to make comparisons, it showed similarities with the current research.                                       
Ungar 200917 was based on primary data from 2002 to 2007 and included economic models 
or RCTs. As a result of the overlap in the search period of the two reviews, four studies49-52 
of Ungar 200917 were captured by the searches of the current review and were excluded.  
Four further studies31,33,35,44 were identified from the common time period of the two reviews 
and were identified from a database used in both reviews but were not included in Ungar 
200917. Therefore, differences in the search strategies of the studies can be assumed.  
Ungar 200917 identified ten studies over the five-year period and included both 
pharmaceutical and non-pharmaceutical interventions, though the number of pharmaceutical 
interventions was lower (30%, vs. 61% in the present review). The non-pharmaceutical care 
interventions were the same as the current review. Similar limitations were detected in the 
two reviews.  
The current review did not show an increasing trend in the total number of EE studies in the 
field of paediatric asthma treatments, however, the proportion of studies examining 
pharmaceutical treatments increased since the previous review17. 
Both reviews emphasised that explicit statements about the perspective of the studies and 
WTP threshold were necessary to interpret the results of EEs. Furthermore, the current 
review confirmed the lack of enough, high-quality research on the matter of childhood 
asthma.  
 
Strengths and Limitations 
This SR searched five databases and followed formerly tested search protocols. An 
additional hand search was carried out. Study selection followed the PRISMA 
recommendations. The search was not limited by the type of EE, intervention or outcome 
measure. However, some limitations need to be noted. Only English language publications 
were considered meaning that potential articles published in other languages were left out. 
Including the use of the CHEERS, the methodology of the studies was not examined by a 
formerly tested checklist. The screening and data extraction were done by one reviewer. 
However, pre-defined criteria for both processes stated in the protocol was applied. One 
additional study53 was identified through the publishing process that was not captured by our 
search strategy but is potentially eligible for inclusion. We acknowledge that this might be a 
limitation of our SR. A
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Conclusion 
There remains a lack of good quality EE studies in the field of paediatric asthma treatments 
and further research is needed for allocation decisions. Research with high quality of 
evidence, relevant and robust methods, which includes studying the long-term effects of the 
treatments is essential. Furthermore, the use of a utility measure validated in children is 
necessary. The use of non-pharmaceutical programs, such as management techniques, 
along with medicines is encouraged as they can improve disease management. Besides, the 
simplification of medication dosing seems to be effective. EE of new technologies adapted to 
local settings is recommended as new treatments can be more cost-effective than the UC or 
standard therapy.  
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Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Flow diagram of the search process 
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Table 1 Results of the CHEERS checklist 
Author CHEERS score† 
Wang, 2011
43
 91% 
Rodriguez-Martinez, 2015
40
 88% 
Petrou, 2014
36
 87% 
Willems, 2007
44
 87% 
Rodriguez-Martinez, 2013
41
 80% 
Noyes, 2012
34
 78% 
Rhee, 2012
38
 78% 
Doull, 2007
31
 76% 
Doan, 2011
30
 72% 
Below average‡ 
Flores, 2009
32
 70% 
Vasbinder, 2016
42
 70% 
Andrews, 2012
27
 68% 
Ostrom, 2005
35
 61% 
Ng, 2006
33
 57% 
Reinhold, 2013
37
 57% 
Burch, 2012
29
 56% 
Atherly, 2009
28
 52% 
Rodriguez, 2008
39
 43% 
 † CHEERS score represents the percentage of ’yes’ answers 
‡ Average score: 70.61%; standard deviation: 13.88% 
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 USA Model 
(Decision 
tree) 
 
CEA 
1. 
prescribed 
ICS 
2. 
dispensed 
ICS 
3.UC 
Hospital-
based 
1. Health 
system (USA)  
2. Societal 
perspective  
1 months  Not 
reported 
Direct + indirect 
costs: UC = 
$27100, Uniform 
prescribing = 
$22000 and 
Uniform dispensing 
= $20100 
 
1. Return to 
ED/100 patients 
within a month 
 
 
ICER not reported 
Total cost saving per 100 patients 
comparing the UC with medication 
dispensing arm is $7000 
Both prescribing and dispensing of 
ICS is an alternative approach 
clinically and financially  
 
68 
B
u
rc
h
, 
2
0
1
2
2
9
 
UK Model 
(Markov 
model) 
 
CUA 
1. 
omalizuma
b + 
standard 
therapy  
2. standard 
therapy 
Not explicitly 
reporter (the 
study 
suggests NHS 
England and 
Wales) 
1. Not 
explicitly 
reported (the 
study 
suggests an 
NHS 
perspective) 
10 years 
 
3.5% actual cost of 
omalizumab at the 
time of the analysis 
was used 
1. QALYs Base-case ICER £91169/QALY 
in a subgroup analysis ICER 
£65911/QALY 
 
ICER threshold: £20000-30000 per 
QALY  
NICE does not recommend the 
routine use of omalizumab  for 
children age 6-11 
 
56 
D
o
a
n
, 
 2
0
1
1
3
0
 
Canad
a 
Model 
 
CEA 
1. MDI   
2. wet 
nebulizatio
n 
Hospital-
based 
1. Hospital Time of the 
ED admission 
to 2 days 
post-ED 
admission 
(average 
admission is 
48-hours) ≈4 
days 
Not 
require 
Treat a patient in 
the ED with : 
- MDI = 
CAN$262.73 
- wet nebulizer= 
CAN$417.68 
1. Disposition from 
ED  
 
ICER -CA$2499.16 
/admission averted 
 
Using MDI may result in 
Can$154.95 net saving per patient 
MDI yield significant cost savings 
for hospitals, HC systems and 
families 
72 
D
o
u
ll,
 2
0
0
7
3
1
 
UK Model 
 
CUA 
1. SFC   
2. FP 
(current 
and 
increased 
dose) 
3. 
(estimates 
for BDP) 
Not reported 1. Not 
reported 
1 year Not 
required 
Price of FP = 
£178.97 
Price of SFC 
(Accuhaler/ 
Evohaler) = 
£379.86/ £230.11 
1. QALYs SFC Evohaler vs increased dose 
FP ICER £15739/QALY  and 
Accuhaler ICER £63736/QALY 
 
SFC compared to FP resulted in 
annual cost saving $47-77 
Switch to SFC is a cost-effective 
approach 
76 
R
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d
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a
rt
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2
0
1
3
4
1
 
Colom
bia 
Model 
(Markov 
model) 
 
CUA 
1. FP 
2. BUD 
3. 
ciclesonide 
4. BDP 
Not reported 1. National 
HC system 
(Colombia) 
12-months Not 
required 
BDP average 
cost/unit= £106.16 
FP average 
cost/patient = 
£231.19 
1. QALYs ICUR (FP vs BDP) 
£19,835.28/QALY 
 
BDP was associated with the 
lowest cost, FP resulted in greatest 
QALYs 
BDP is the most cost-effective 
method to threat paediatric 
patients, when WTP is less than 
£21,129.22/QALY, otherwise FP, 
which has 18% probability for being 
cost-effective at WTP 
£9803.96/QALY 
80 
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5
4
0
 
Colom
bia 
Model 
(Markov 
model) 
 
CUA 
1. daily ICS 
therapy 
2. 
intermittent 
ICS therapy  
School-based 1. National 
HC system 
(Colombia) 
12-months 
 
 
Not 
required 
School patients: 
Daily ICS=$437.02 
Intermittent=$585.0
3 
 
Prechool patients: 
Daily ICS=$704.02 
intermittent=$749.8
1 
1. QALYs ICER was not calculated as the 
daily therapy was dominant 
 
School children: 
daily therapy had lower costs and 
greater gain in QALYs (0.9629 vs 
0.9392) on average /patient over 
the 12 months. 
Pre-schoolers: daily therapy also 
had lower costs and greater gain in 
QALYs (0.9238 vs 0.9130 QALY on 
average /patient over the 12 
months. 
 
Daily therapy is more cost-effective 
with greater gain in QALYs and 
lower total treatment costs 
88 
ICS- Inhaled corticosteroids; UC- Usual care ; MDI- Metered-dose inhaler ; FP- Fluticasone propionate; BUD- Budesonide; BDP- Beclomethasone dipropriate; SFC- Salmeterol; ED- emergency-related; 
QALY- Quality-adjusted life year; ICER- Incremental cost-effectiveness ratio; ICUR- Incremental cost-utility ratio; HC – Health Care 
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USA Quasi-
experiment
al 
 
CEA 
1. “Power 
Breathing” 
educational 
intervention 
2. control 
group 
School-based 1. Societal 3-months 
follow-up 
Not 
reported 
Annualized cost to 
respondent was 
estimated to be 
$6,500, 
 $30.37 per student 
1. SFD Not reported 
The program showed a statistically 
significant impact with greater 
decline in symptoms in the 
intervention group.  The program 
costs approx. $3.9/symptom free 
day gained. Other interventions 
(BUD) cost approx. $11/SFD 
gained. 
Power Breathing interventions is 
cost-effective. 
52 
F
lo
re
s
, 
2
0
0
9
3
2
 
USA RCT 
 
CEA 
1. PM  
2. 
traditional 
asthma 
care 
Hospital-
based 
1. Not 
reported 
1 year Not 
reported 
- Average monthly 
cost for PM per 
patient = $60.42, 
- Intervention cost = 
$120.84/child 
 
1. Reduction of 
asthma 
exacerbation days 
ICER -$597.10 
/asthma exacerbation-free days 
gained,  
For high-participation group 
(attended ≥25% of meetings and 
completed ≥50% of telephone 
contacts) ICER 
-$46.16/ asthma exacerbation-free 
days gained 
PMs are associated with 
reasonable costs and net savings 
70 
N
g
, 
2
0
0
6
3
3
 
Hong 
Kong 
Prospective 
randomised 
single 
blinded 
controlled 
trial 
 
CEA 
1. Intensive 
asthma 
education 
program 
(B) 
2.  standard 
asthma 
education 
program 
(A) 
Hospital-
based 
1. Not 
reported 
3 months  Not 
reported 
Average cost of 
public ward 
services is  
HK$1702/day 
Hospitalisation in 
standard 
program/child 
HK$6213 and 
HK$5003 in the 
intensified program. 
Extra cost in group 
B is nursing 
fee/hour HK$241/ 
patient. 
1. Number of visits  
to the ED 
2. Number of 
hospitalisations 
Not reported 
 
Improved health outcomes and the 
net saving is HK$969/ patient. 
Intensive asthma education 
program might be more cost-
effective 
57 
N
o
y
e
s
, 
2
0
1
2
3
4
 
USA Based on 
SBAT Trial 
 
CEA 
1.  School-
Based 
Asthma 
Therapy 
2. UC 
School- based 1. Medicaid One school 
year 
(approximatel
y 7-9 months) 
Not 
reported 
SBAT program 
costs= $4822 
/100 children/ 
month, 
Total costs: 
SBAT=$12463 
UC=$10880 
1. SFD Total direct costs: $28 per SFD 
95%CI( 418 to 75) 
 
Total costs: $10 per SFD gained (-4 
to 46) 
 
The net saving due to the 
intervention was $3,240. SBAT 
schools could save on average 
$1,146 in lost revenue compared to 
UC schools. 
 
SBAT was cost-effective in 
reducing symptoms in urban 
children with asthma compared to 
existing programs 
78 
O
s
tr
o
m
, 
2
0
0
5
3
5
 
USA Randomise
d double-
blind, 
double-
dummy, 
parallel-
group study 
 
CEA 
1. FP  
2. MON 
Hospital-
based 
1. Not 
reported 
12 weeks Not 
reported 
Daily cost for FP 
was $1.08, for 
MON $3.05 and 
$0.11/puff for 
albuterol; costs for 
asthma related 
outpatient/clinic 
visits($286.85) and 
hospitalisation 
($3,796) 
1. Percent change 
in morning pre-
dose FEV1 
Not reported 
 
Main daily total asthma-related 
cost/patient in the FP group was 
approx. one third of the costs in 
MON ($1.25 SD=0.41 vs $3.49 
SD=0.5); the total asthma-related 
costs/ successfully treated patient 
(achieved ≥15%FEV1) was lower in 
FP group compared to MON group 
($4.03 vs $17.45). 
 
Asthma-related costs are lower in 
FP and it is also more effective 
61 
P
e
tr
o
u
, 
 2
0
1
4
3
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UK Prospective 
RCT 
 
CEA, CUA 
1. MgSO4 
2. isotonic 
saline 
(placebo) 
Hospital-
based  
 
1. NHS  
2. personal 
social 
services 
The time 
horizon 
extended to 
discharge and 
to 
1 month post-
randomization 
for the 
purposes of 
the CUA 
Not 
required 
Mean total health 
and social service 
(societal) cost were 
GBP1,067 (GBP 
1,157) in MgSO4 
GBP 1,119 
(GBP1,202) in the 
placebo group 
1. unit change in 
ASS (CEA) 
2.  QALYs (CUA) 
CEA: ICER £189/unit decrement in 
ASS and it had 75.1% probability of 
being cost-effective at £1000  unit 
per decrement in ASS threshold 
and 36.6% probability of being less 
costly 
 
CUA: MgSO4 had a 67.6% 
probability of being cost-effective at 
a £20000/ QALY gained threshold 
and 69.1$ probability of being less 
costly 
 
The probability of CE of nebulized 
MGSO4, given as an adjuvant to 
standard treatment is less than 
70% across accepted CE threshold 
for an additional QALY 
87 
R
e
in
h
o
ld
, 
2
0
1
3
3
7
 
Germ
any 
Piggy back 
analysis – 
randomized 
control 
multi-center 
study 
 
CEA, cost-
analysis, 
break even 
analysis 
1. SCIT 
with 
asthma 
medication  
2.  asthma 
medication 
only 
Not reported 
 
1. Not 
reported 
3-years  3% SCIT in 2012 were 
assumed to be 
about €1597 over 
the 3-years 
intervention period 
Total mean costs 
per patient for SCIT 
770€ 95%CI [701 
to 839] and for 
controls €383 
95%CI [317 to 449] 
1. Mean annual 
morning peak flow 
Not reported 
 
SCIT (with Acraoid) is associated 
with superior effectiveness, the 
mean adjusted morning peak flow 
over the 3 years of SCIT 
intervention shows higher values. 
The probability that SCIT leads to 
superior effectiveness compared to 
controls is about 90% 
 
Intervention reduces asthma 
medication intake and has cost-
saving effects 
57 
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USA Prospective 
study 
design, 
data 
collected 
from a 
randomised 
controlled 
study 
 
CBA 
1. Peer-led 
asthma 
self-
manageme
nt program 
2. adult led 
asthma 
self-
manageme
nt progam 
School- and 
hospital- 
based 
1. Not 
reported  
 
9-months  Not 
reported 
Total costs: 
- Peer-led 
program= $7955  
- Adult-led program 
=$7305.  
 
Individual costs: 
- Peer-led program 
= $64/capita 
- Adult-led 
program= 
$99/capita 
1. Net cost savings 
 
Not applicable 
The peer-led group one had fewer 
acute office visits than the adult-led 
group. 
At 3-months follow-up, compared to 
adult-led program, the net cost 
saving from the peer-led program 
was $5.8 /person, which reflected 
$11 more/person for the cost of the 
peer-led program offset by $16.8 
less/person associated with acute 
office visits, assuming the average 
costs for an office visit to be $80 in 
2008 USD. The net cost savings in 
non-research setting was estimated 
to be$51.8/person for a 3-months 
period. 
 
Peer leaders can potentially yield 
health care cost savings through 
the reduction in acute office visits in 
comparison to a traditional program 
led by healthcare professionals. 
 
 
Note: In an additional subgroup 
analysis the sample size was 
smaller than 20, though the base-
case analysis was appropriate for 
the criteria of this SR. 
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Vene
zuela 
Prospective 
double-
blinded 
RCT 
 
CMA 
1. 
Nebulised 
Formoterol 
Fumarate 
powder 
single dose 
(FF)  
2. 3 dose of 
nebulised 
Albuterol 
ampoules 
Hospital- 
based 
1. Not 
reported 
Not reported Not 
reported 
Nebulised FF 
single dose = 
US$1.35 and 3 
dose of Albuterol= 
US$6.73 
1. Cost of treatment  
2. Health outcomes  
Not applicable 
 
1 dose of Nebulised FF seems to 
be equivalent to 3 doses of 
nebulised Albterol. FF is a simpler 
and more cost-effective approach. 
 
FF is a simpler and a more cost-
effective approach. 
43 
V
a
s
b
in
d
e
r,
 2
0
1
6
4
2
 
The 
Neth
erlan
ds 
Multicentre 
RCT 
 
CEA 
 
 
 
 
 
 
 
 
 
 
 
1. Real-
Time 
medication 
monitoring 
(RTMM)+ 
tailored 
SMS 
(interventio
n group)  
2. RTMM 
alone 
(control 
group) 
Hospital-
based 
1. Healthcare 
(the 
Netherlands2. 
societal 
12 months Not 
reported 
Total costs in 
intervention group 
from health care 
perspective: €731 
and from societal 
perspective: €1,043 
Total costs in 
control group from 
health care 
perspective: €636 
and from societal 
perspective: €764 
1. Adherence to 
ICS 
2. Asthma control 
3. QoL 
4. Frequency of 
asthma 
exacerbation 
No reported 
 
No difference in asthma control, 
QoL, exacerbation and adherence 
improved. 
Higher cost in intervention group. 
Apart from the cost of SMS 
intervention there was no difference 
in costs and there was no evidence 
on better asthma control, improved 
asthma-specific QoL or fewer 
asthma exacerbation. 
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USA Randomize
d, 
controlled, 
double-
blind trial 
 
 
CEA 
1. FP  
2. MON 
Study centres 
- based 
1. Health-care 
(USA) 
2. third party 
payer 
3. societal 
 
48-weeks Not 
reported 
Direct costs: $759 
for FP and $1,189 
for MON. 
Societal costs:  
$1075 for 
fluticasone, $1,673 
for montelukast. 
 
1. Asthma-control 
days (ACD)  
2. Improvement in 
FEV1 
3. Number of 
exacerbations 
avoided 
 
ICER -$11 / 1 more ACD gained 
 
The probability of FP being cost-
effective is at least 95% considering 
sampling uncertainty 
FP had lower costs and higher 
effectiveness 
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The 
Neth
erlan
ds 
Single-
centre 
Prospective 
RCT 
 
CUA 
 
1. Nurse-
led tele-
monitoring 
program 
2. UC 
Hospital-
based 
1. health-care 
(the 
Netherlands) 
2. societal 
12 months  Not 
reported 
Total costs      
(mean/SD/)=interve
ntion group 
€1206/601/ and 
control group 
€597/863/ 
1. QALYs Health care perspective: ICER 
€58,726/QALY,  
Societal perspective: 
ICER €59,071/QALY gained 
 
Probability 68% at a ceiling ration 
€80000/QALY and 22% at a ceiling 
ratio of € 40000/QALY gained from 
societal perspective. When monitor 
cost were left out the effectiveness 
ratio changed from 68% to 93% 
and all the costs decreased 
 
The nurse led tele-monitoring 
program is not cost saving in 
children 
87 
SFD-Symptom-free day; PM- Parent mentor; UC- Usual care; SBAT- School-Based Asthma Therapy; FP- Fluticasone propionate; MON- Montelukast; MgSO4- Magnesium sulfate; SCIT- 
Subcutaneous Specific Immunotherapy; FF- Formoterol Fumarate ; RTMM- Real-time medication monitoring ; ACD- Asthma-control day; QALY- Quality-adjusted life year; ICER- Incremental cost-
effectiveness ratio; BU 
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/A
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Title 1 Y N N Y N Y N Y Y N Y Y Y N Y Y Y Y 66.67% 33.33% - - 
Abstract 2 N Y Y Y Y Y Y Y U N Y Y Y N Y Y Y Y 77.78% 16.67% 5.56% - 
Introduction 
Background and 
objectives 
3 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 100.00% - - - 
  Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 100.00% - - - 
Methods 
Target population and 
subgroups 
4 Y Y Y Y Y Y U Y Y Y Y Y N Y Y Y Y Y 88.89% 5.56% 5.56% - 
Setting and location 5 Y Y Y Y Y Y N Y Y Y Y Y Y U Y N N Y 77.78% 16.67% 5.56% - 
Study perspective 6 Y N N Y N Y N N N Y Y Y Y U Y N Y Y 55.56% 38.89% 5.56% - 
Comparators 7 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y U U 88.89% - 11.11% - 
Time horizon 8 Y Y Y Y Y Y Y Y N Y Y Y Y Y Y Y Y Y 94.44% 5.56% - - 
Discount rate 9 N N N N N Y Y N N N N N Y Y Y Y Y Y 44.44% 55.56% - - 
Choice of health 
outcomes 
10 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 100.00% - - - 
Measurement of 
effectiveness 
11a† Y Y Y N Y Y Y Y Y Y Y Y - - - - - - 91.67% 8.33% - - 
 11b‡ - - - - - - - - - - - - U U N Y Y Y 50.00% 16.67% 33.33% - 
Measurement and 
valuation of preference-
based outcomes 
12 N/A N/A N/A N/A N/A Y N/A N/A N/A N/A N/A Y N/A Y N/A Y Y Y 33.33% - - 66.67% 
Estimating resources 
and costs 
13a* N N N Y Y Y Y Y N Y Y Y - - - - - - 66.67% 33.33% - - 
 13b‡ - - - - - - - - - - - - Y U Y Y Y Y 83.33% - 16.67% - 
Currency, price date, 
and conversion 
14 N N N Y N Y N Y N Y Y Y Y N U Y Y Y 55.56% 38.89% 5.56% - 
Choice of model 15‡ - - - - - - - - - - - - Y Y U U Y Y 66.67% - 33.33% - 
Assumptions 16‡ - - - - - - - - - - - - Y Y Y Y Y Y 100.00% - - - 
Analytical methods 17 N Y Y Y Y Y Y Y Y Y Y Y N N Y Y N N 72.22% 27.78% - - 
Results 
Study parameters 18 Y Y Y Y Y Y Y Y N Y Y Y N N N Y N N 66.67% 33.33% - - 
Incremental costs and 
outcomes 
19 N Y Y Y Y Y N Y N U Y Y N Y Y Y Y Y 72.22% 22.22% 5.56% - 
Characterising 
uncertainty 
20a† N N N N N Y N N N Y Y Y - - - - - - 33.33% 66.67% - - 
 20b‡ - - - - - - - - - - - - N Y Y N Y Y 66.67% 33.33% - - 
Characterising 
heterogeneity 
21 N/A Y N/A N/A N/A N/A N/A N/A N/A N/A Y N/A N/A U N/A N/A Y Y 22.22% - 5.56% 72.22% 
Discussion 
Study findings, 
limitations, 
generalisability, and 
current knowledge 
22 U Y Y Y N U Y Y Y U Y Y Y U Y Y Y Y 72.22% 5.56% 22.22% - 
Other 
Source of funding 23 N Y N Y N N Y Y N Y Y N Y Y N Y N Y 55.56% 44.44% - - 
Conflicts of interest 24 Y Y N Y Y Y U Y N Y Y Y Y Y Y U Y Y 77.78% 11.11% 11.11% - 
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   52% 70% 57% 78% 61% 87% 57% 78% 43% 
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% 
87% 68% 56% 72% 76% 80% 88%     
†only applicable in trials; ‡only applicable in models; §Total score for trials: 23; Total score for models: 25 
